Drugs / MSB0254
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | — | 2018-08-28 | “On August 28th, 2018, Mabspace submitted another IND application to NMPA for MSB0254, the second product candidate from the platform.” transcenta.com ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04381325 | Apr 2020 → Jun 2022 | neoplasm | Suzhou Transcenta Therapeutics Co., Ltd. | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2018-09-05 | Suzhou Transcenta Therapeutics Co., Ltd. | Regulatory MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA transcenta.com ↗
On August 28th, 2018, Mabspace submitted another IND application to NMPA for MSB0254, the second product candidate from the platform. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-11-25 | Suzhou Transcenta Therapeutics Co., Ltd. | Transcenta Announces First Patient Dosed in Phase Ib Clinical Trial of its Humanized Anti-VEGFR-2 Monoclonal Antibody MSB0254 transcenta.com ↗ |
| 2018-09-05 | Suzhou Transcenta Therapeutics Co., Ltd. | MabSpace Biosciences Doses First Patient in China Phase 1 Trial for MSB2311 and Submitted IND for MSB0254 to NMPA transcenta.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSB0254 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04381325 ↗ |
| Route | Intravenous | “administered intravenously” NCT04381325 ↗ |